11 February 2012

CustomVis rebuffs rebels

15/06/2009

CustomVis's laser is being trialed by London's world-leading Moorfields Eye Hospital

CustomVis's laser is being trialed by London's world-leading Moorfields Eye Hospital

Laser eye surgery innovator CustomVis claims the support of its largest shareholder against an attempted coup from a group of former directors.

Canny investor and serial AIM chairman Bob Morton, who owns 22.2 per cent of AIM-listed CustomVis, is ‘very supportive’, insists CEO Paul van Saarloos, ahead of a general meeting requisitioned for Monday 6 July at the company’s London registered office. In response to the demand from the requisitioners – erstwhile directors Simon Gordon, Mukesh Jain and William Colvin – to have Van Saarloos removed from his position, he bashfully admits Morton, who has no plans to join the board yet, has described him as ‘the best CEO in the world for the company’.

Van Saarloos, the inventor of the company’s Pulzar 1 solid-state laser, adds that the plans of these former directors would herald 'a return to the bad old days [of the company]’. He argues that their proposal to run the Australia-based company from Gordon's Scotland base 'would increase the cash burn rate’ and would be foolhardy due to their ‘lack of CEO experience’.

Furthermore, CustomVis has filed a counter-claim against former sales director Jain, who served a writ on the company for additional payment, alleging that he offered customers discounts in return for personal payments.

Van Saarloos believes Gordon, Jain and Colvin have launched this revolt as the fortunes of the company have taken a turn for the better, thanks in part to the improved commercial approach and corporate governance introduced by new chairman Simon Caroll. With £2.4 million owed by debtors on long-term payment plans, and five sales contracts for Pulzar in May and June, the company is eyeing break-even.

‘With our cash burn down we don’t need to sell that many lasers a month to become cash-flow positive,’ says van Saarloos. ‘it used to have to be three. Now it’s about one and a half.’

CustomVis shares, though up from their all-time low of 0.25p to 1.6p since January, have proved dire performers since their AIM debut at 91p in 2003. The highly influential Morton first bought in through his Hawk vehicle 18 months ago at 5p, then topped up at lower levels last October.

Tags: AIM, Boardroom moves, Breaking-even, Penny shares, Technology

Sector: Health Care Equipment & Services

Companies: CustomVis (suspended on 19 April, 2010)

Subscribe today


Subscribe today and save 50%. Receive company watch recommendations and extensive company profile tips, released two months ahead of the market.

Sign up here

Spread Trading. New from Halifax Share Dealing

£100 credit when you open five trades within 60 days – terms apply. Spread Trading is not for everyone please ensure you understand the risks as you may lose more than your initial deposit. Click here for more information.

Institutional Investors in AIM 2011 - New Report

This unique study analyses the shareholdings of companies listed on AIM, extracting trends including rankings of the value and number of their investments.
Please click here to order your copy of the report or call 0207 250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

If you're interested in business tax updates visit our specialist tax guide website.

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Vernalis to raise £68.5m 10/02/2012

Drug discoverer Vernalis (VER) is to raise £68.5 million as part of a joint venture with US concern Tris Pharma.

Tags: FTSE fledgling, Fundraising, Raising money

Sector: Pharmaceuticals & Biotechnology

Companies: Vernalis

Magnolia buys Lime 10/02/2012

Magnolia Petroleum (MAGP) has acquired 800 acres in the Mississippi Lime formation in Oklahoma.

Tags: Acquiring lime formation, Magnolia Petroleum, Oil and gas explorer

Sector: Oil & Gas Producers

Companies: Magnolia Petroleum

Condor encourages on La India
10/02/2012

Gold explorer Condor Resources (CNR) has reported encouraging results from drilling at its La India project in Nicaragua.

Tags: AIM mining concerns, Business in Nicaragua, Drilling in Central America, Gold explorer

Sector: Mining

Companies: Condor Resources

Nighthawk remains jolly 09/02/2012

US-focused Nighthawk Energy is launching a $7.5 million program to invest in its Colorado-based Jolly Ranch project.

Tags: AIM-quoted business, Doing business in the US, Drilling new wells, Investing in Colorado

Sector: Oil & Gas Producers

Companies: Nighthawk Energy

Tower raises £5.4m 09/02/2012

Africa-focused Tower Resources (TRP) has raised £5.4 million via a placing with a mixture of institutional investors and directors.

Tags: Doing business in Africa, Doing business with New Jersey, Placing, Unusual financing arrangements

Sector: Oil & Gas Producers

Companies: Tower Resources

Thomas nurses £91m loss 08/02/2012

Beleaguered travel operator Thomas Cook (TCG) has reported a loss of £91 million its first quarter also announcing the sale of its Indian division.

Tags: Doing business in India, Sale of subsidary, Travel and leisure, Travel operator

Sector: Travel & Leisure

More News

Sectors